3D Glioblastoma ex vivo
CompanyNeuron-D GmbH, Dresden, Germany
Glioblastoma multiforme (GBM) is the most common malignant brain tumor among adult patients and is almost universally fatal. Despite the recent leaps in knowledge about the genome, epigenome, and transcriptome of GBM, clinical outcomes in GBM have not changed over the years. To investigate this disease the company Neuron D has developed a 3D cell culture drug testing platform for glioblastoma multiforme (GBM).
The 3D platform is based on the 3D starPEG-Heparin hydrogel technology. It enables drug developers to test the efficacy, safety and pharmacokinetics of candidate compounds for GBM in a three-dimensional, physiologically relevant tumor environment.
3D Glioblastoma ex vivo
www.neurond.de
Added on: 11-21-2022
[1] https://neurond.de/3d-glioblastoma-ex-vivo